Topical paromomycin for new world cutaneous leishmaniasis

PLoS Neglected Tropical Diseases

Volumn 13, Issue 5, 2019, Pages

  Sosa, Néstor ^a   Pascale, Juan Miguel ^a   Jiménez, Ana I ^a,g   Norwood, Jeanne A ^b   Kreishman Detrick, Mara ^c   Weina, Peter J ^d   Lawrence, Kendra ^b   McCarthy, William F ^b   Adams, Ryan C ^b   Scott, Charles ^e   Ransom, Janet ^e   Tang, Douglas ^e   Grogl, Max ^f  

^a Instituto Conmemorativo Gorgas de Estudios de la Salud   (Panama)

^b US Army Medical Materiel Development Activity   (United States)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

^e Fast Track Drugs and Biologies LLC   (United States)

^f Peru   (Peru)

^g EAP Marc Aureli ICS Barcelona Ciutat   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; GENTAMICIN; HEAT SHOCK PROTEIN 70; PAROMOMYCIN; ANTIPROTOZOAL AGENT;

ADOLESCENT; ADULT; AGED; APPLICATION SITE DERMATITIS; APPLICATION SITE INFECTION; APPLICATION SITE PRURITUS; ARTHROPOD BITE; ARTICLE; BACTERIAL SUPERINFECTION; BACTERIUM CULTURE; CHILD; CLINICAL OUTCOME; CONTACT DERMATITIS; CONTROLLED STUDY; DERMATITIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; EROSION; ERYTHEMA; FEMALE; FOLLICULITIS; FOLLOW UP; HEADACHE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTRANSAMINASEMIA; LEISHMANIA; LEISHMANIA GUYANENSIS; LEISHMANIA PANAMENSIS; LEISHMANIASIS; LYMPHANGITIS; MAJOR CLINICAL STUDY; MALE; MUCOSAL DISEASE; MUCOSAL LEISHMANIASIS; MULTILOCUS ENZYME ELECTROPHORESIS; PAIN; PHASE 3 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RECURRENT DISEASE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RHINITIS; RHINOPHARYNGITIS; SKIN DEFECT; SKIN EROSION; SKIN LEISHMANIASIS; TREATMENT FAILURE; TREATMENT RESPONSE; TREATMENT RESPONSE TIME; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECT; LEISHMANIA MAJOR; MIDDLE AGED; PARASITOLOGY; PHYSIOLOGY; PRESCHOOL CHILD; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME; TUNISIA; YOUNG ADULT;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AGED; ANTIPROTOZOAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; GENTAMICINS; HUMANS; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MALE; MIDDLE AGED; PAROMOMYCIN; TREATMENT OUTCOME; TUNISIA; YOUNG ADULT;

EID: 85065578192     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0007253     Document Type: Article

References (20)

1. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J et al. Leishmaniasis Worldwide and Global Estimates of Its Incidence. PLoS One. 2012; 7(5):e35671. https://doi.org/10.1371/journal.pone. 0035671 PMID: 22693548
2. Hepburn NC. Cutaneous leishmaniasis: an overview. J Postgrad Med. 2003; 49(1):50–54. PMID: 12865571
3. Gontijo B, de Carvalho Mde L. American cutaneous leishmaniasis (Article in Portuguese). Rev Soc Bras Med Trop. 2003; 36(1):71–80. PMID: 12715066
4. Control of the leishmaniasis: WHO technical report series no. 949. Geneva: World Health Organization, 2010.
5. Chaves LF, Calzada JE, Valderrama A, Saldana A. Cutaneous leishmaniasis and sand fly fluctuations are associated with el Niño in Panamá. PLoS Negl Trop Dis. 2014 Oct 2; 8(10):e3210.https://doi.org/10.1371/journal.pntd.0003210 eCollection 2014 Oct. PMID: 25275503
6. Miranda A, Carrasco R, Paz H, Pascale J, Samudio F, Saldana A, et al. Molecular epidemiology of American tegumentary leishmaniasis in Panama. Am J Trop Med Hyg. 2009; 81(4):565–571. https://doi.org/10.4269/ajtmh.2009.08-0265 PMID: 19815867
7. Reithinger R, Dujardin J, Louzir H, Pirmez C, Alexander B, Brooker S, et al. Cutaneous leishmaniasis. Lancet Infect Dis. 2007; 7(9):581–596. https://doi.org/10.1016/S1473-3099(07)70209-8 PMID: 17714672
8. Guía para el abordaje integral de la leishmaniasis en Panamá, 2015. Ministry of Health of Panama (MINSA), Social Security Hospital (CSS) and Panamerican Health Organization (PAHO).
9. Soto J, Toledo J, Vega J, Berman J. Short Report: Efficacy of Pentavalent Antimony for Treatment or Colombian Cutaneous Leishmaniasis. Am J Trop Med Hyg. 2005; 72(4):421–422. PMID: 15827279
10. Soto J, Soto P. Current situation and future of antileishmanial therapy in Colombia. Biomédica 2006; 26 (Supl.1):194–206. Review. Spanish. PMID: 15827279
11. Gasser R Jr, Magill A, Oster C, Franke E, Grögl M, Berman J. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clin Infect Dis. 1994; 18(1):83–90. PMID: 7519887
12. Palacios R, Osorio L, Grajalew L, Ochoa M. Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania viannia species. Am J Trop Med Hyg. 2001; 64 (3–4):187–193. PMID: 11442216.
13. Ben Salah A, Ben Messaoud N, Guedri E, Zaatour A, Ben Alaya N, Bettaieb J, et al. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. N Engl J Med. 2013; 369:524–532. https://doi.org/10.1056/NEJMoa1202657 PMID: 23388004.
14. Grogl M, Schuster BG, Ellis WY, Berman J. Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (Aminosidine) and gentamicin. J Parasitol. 1999; 85(2):354– 359. PMID: 10219319.
15. Sosa N, Capitán Z, Nieto J, Nieto M, Calzada J, Paz H, et al. Randomized, Double-blinded, Phase 2 Trial of WR 279,396 (Paromomycin and Gentamicin) for Cutaneous Leishmaniasis in Panama. Am J Trop Med Hyg. 2013; 89(3):557–563. https://doi.org/10.4269/ajtmh.12-0736 PMID: 23857024.
16. Montalvo AM, Fraga J, Maes I, Dujardin J, Van der Auwera G, et al. Three new sensitive and specific heat-shock protein 70 PCRs for global Leishmania species identification. Eur J Clin Microbiol Infect Dis. 2012; 31:1453–1461. https://doi.org/10.1007/s10096-011-1463-z PMID: 22083340.
17. Thomaz-Soccol V, Velez ID, Pratlong F, Agudelos S, Lanotte G, Rioux J, et al. Enzymatic polymorphism and phylogenetic relationships in Leishmania Ross, 1903 (Sarcomastigophora: Kinetoplastida): a case study in Colombia. Syst Parasitol. 2000; 46(1):59–68. PMID: 10803436.
18. Cruz A, Rainey P, Herwaldt B, Stagni G, Palacios R, Trujillo R, et al. Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate. J Infect Dis. 2007; 195(4):602–608. https://doi.org/10.1086/510860 PMID: 17230422.
19. Machado-Coelho G, Caiaffa W, Genaro O, Magalhães P, Mayrink W. Risk factors for mucosal manifestation of American cutaneous leishmaniasis. Trans R Soc Trop Med Hyg. 2005; 99(1):55–61. https://doi.org/10.1016/j.trstmh.2003.08.001 PMID: 15550262.
20. Blum J, Lockwood D, Visser L, Harms G, Bailey M, Caumes E, et al. Local or systemic treatment for New World cutaneous leismaniasis? Re-evaluating the evidence for the risk of mucosal leishmanisis. Int Health. 2012; 4(3):153–163 https://doi.org/10.1016/j.inhe.2012.06.004 PMID: 24029394.